Back HIV Prevention

CROI 2015: Smoking Outweighs HIV-Related Risk Factors for Non-AIDS Cancers

Smoking appears to contribute most to the burden of non-AIDS-defining cancers diagnosed in people living with HIV in the U.S., out of all the potential modifiable risk factors -- including hepatitis B or C, low CD4 cell count, an AIDS diagnosis, or having an unsuppressed viral load -- according to a study reported last week at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

CROI 2015: Screening Finds High Prevalence of Early-Stage Lung Cancer in Smokers with HIV

Using low-dose computed tomography to screen selected people living with HIV who smoke led to early lung cancer diagnoses at younger ages than normally seen in the general population, according to findings from the ANRS EP48 HIV CHEST study reported last week at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

Coverage of the 2015 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.

Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.

HIVandHepatitis.com coverage by topic

CROI website

3/2/15

alt

CROI 2015: Varenicline Helps People with HIV Stop Smoking, but Success Rate Remains Low

The smoking cessation drug varenicline (Chantix) helped more people with HIV to stop smoking than counseling alone, but less than 20% were able to remain abstinent for a year, according to the results of a French study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.The smoking cessation rates in this study were comparable to those previously seen for HIV-negative people using varenicline or other methods -- across the board only a minority manage to quit long-term.

alt

Read more:

CROI 2015: Tenofovir Alafenamide as Effective but Safer for Kidneys and Bones than TDF

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil fumarate (TDF), according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle. A second study showed that TAF has less detrimental effects on the kidneys and bones compared with TDF. TAF has been submitted for approval in the U.S. and Europe.

alt

Read more:

CROI 2015: Smoking and Its Detrimental Outcomes for People with HIV

Smoking and its consequences was a major topic at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Researchers presented findings on smoking as a risk factor for cancer, CT scans to detect early lung cancer, and varenicline for smoking cessation.

Smoking Outweighs HIV-Related Risk Factors for Non-AIDS Cancers

Screening Finds High Prevalence of Early-Stage Lung Cancer in Smokers with HIV

Varenicline Helps People with HIV Stop Smoking

3/4/15

alt

CROI 2015: Putting On Too Much Weight After Starting ART Increases Chronic Inflammation

A return to normal weight after starting antiretroviral therapy (ART) can be beneficial for very sick, underweight individuals living with HIV -- but further weight gain appears to increase markers of inflammation associated with metabolic complications and poorer survival, according to a study reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: HIV Attachment Inhibitor BMS-663068 Shown Safe and Effective in Phase 2b Study

Bristol-Myers Squibb's BMS-663068 or fostemsavir, a first-in-class HIV attachment inhibitor that stops the virus from binding to and entering cells, was well-tolerated and demonstrated good antiviral activity in a study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Related research showed that BMS-663068 can safely be taken with antiretrovirals commonly used by treatment-experienced patients. A Phase 3 trial is now underway.

alt

Read more:

CROI 2015: The Quest for a Cure for HIV [VIDEO]

Research towards a cure for HIV continues, despite some recent setbacks. Several investigators presented their work in a session on HIV persistence, latency reversal, and viremia rebound at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) this week in Seattle. There is still enthusiasm in the HIV cure field, said John Mellors of the University of Pittsburgh, but progress will be slow.

alt

Read more:

CROI 2015: Treatment Cascades and Viral Load Surveys Inform ART as Prevention in Africa

Reaching ambitious HIV prevention targets in South Africa will require intensified efforts to engage and retain men and young people in care, in order to increase the proportion of people on HIV treatment with suppressed viral load, according to a national study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) last week in Seattle. Another study, conducted in 3 countries in sub-Saharan Africa, showed that to maximize the preventive effect of antiretroviral therapy (ART), efforts to expand treatment coverage need to focus on those with the highest viral load off treatment -- mainly people who are already eligible for treatment under current guidelines.

alt

Read more:

CROI 2015: HIV Care in New York City [VIDEO]

Timely linkage to HIV care increased to 76% and achievement of viral suppression within a year of starting antiretroviral treatment rose to almost 70% over the past several years in New York City, but there are still notable disparities across population subgroups and more remains to be done, according to a study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: Study Finds High Rates of Cancer Among Elderly People with HIV

Elderly people living with HIV (over the age of 65) are at greatly increased risk of HIV-associated cancers, though many of the most commonly diagnosed cancers may be related more to aging than to HIV itself, according to a study reported last week at the at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).

alt

Read more:

CROI 2015: HIV Maturation Inhibitor BMS-955176 Looks Promising In Early Study

A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class, researchers reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.

alt

Read more:

CROI 2015: Maraviroc Levels in Vaginal and Rectal Tissues May Not Be High Enough for PrEP

Levels of the HIV entry inhibitor maraviroc (Selzentry) in vaginal and rectal tissues did not reach high enough levels with a single oral dose to confer protection against HIV in a laboratory study, researchers reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Multiple doses, however, could still potentially be effective for pre-exposure prophylaxis, or PrEP.

alt

Read more:

CROI 2015: Week-on, Weekend-Off HIV Treatment Controls Viral Load in Young People

Taking an efavirenz-based antiretroviral regimen during the week and taking no medication on 2 days over the weekend was just as effective as daily treatment at controlling viral load in an 11-country trial of adolescents and young people, Karina Butler from Our Lady’s Children’s Hospital in Dublin reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.

alt

Read more:

CROI 2015: Disappointing Result for Tenofovir Gel Microbicide

Among some highly promising results from HIV prevention studies presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle, there was one disappointment. FACTS 001, a study testing the efficacy against HIV of a vaginal microbicide gel containing tenofovir, produced a null result: there was no difference in the HIV infection rate for young women given the active gel and the rate for those given a placebo gel.

alt

Read more:

CROI 2015: Weekends Off Treatment Works Well for Some Young People with HIV [VIDEO]

Taking breaks from antiretroviral therapy on the weekend did not lead to viral rebound or other problems for adolescents and young adults who had prolonged viral suppression on efavirenz-based regimens, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: Tenofovir Vaginal Gel Not Effective Overall Against HIV [VIDEO]

The FACTS 001 trial evaluating a vaginal microbicide gel containing tenofovir did not show overall effectiveness for preventing HIV infection among young women in South Africa, although the product did appear to provide some protection for women who were able to use it consistently, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.

alt

Read more:

CROI 2015: PrEP Use Rising in San Francisco, but Scale-Up Could Cut New Infections

Use of Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis, better known as PrEP, is increasing in San Francisco, but it is still only reaching about one-third of people who could benefit, and wider use could reduce new HIV infections by 70%, according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.

alt

Read more:

CROI 2015: Similar Fat Gain Seen with Different Antiretroviral Regimens [VIDEO]

People starting antiretroviral therapy containing raltegravir (Isentress) and those starting boosted atazanavir (Reyataz) or darunavir (Prezista) experienced significant increases in both abdominal and limb fat, with no evidence of greater fat gains among those taking HIV protease inhibitors, according to findings presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.

alt

[Grace McComsey, CROI, February 26, 2015]

"We saw a significant increase in peripheral and central fat with all the regimens," McComsey said, describing results from the ACTG 5260s substudy at a CROI press conference. "We used to think protease inhibitors were associated with central fat accumulation, but here even an integrase inhibitor made patients gain as much fat."

She added, however, that people who started antiretroviral therapy before they experienced advanced immune suppression gained less fat, suggesting that this is another reason to start people on treatment "right away, regardless of CD4 count."

3/3/15

Reference

GA McComsey, C Moser, JS Currier, et al. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors
. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 140.

CROI 2015: PrEP Stops 86% of HIV Infections in PROUD Study

A study of pre-exposure prophylaxis (PrEP), the English PROUD study, demonstrated the highest effectiveness yet seen for this method of HIV prevention, the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle heard today. The effectiveness was 86%; for every 20 infections that might have occurred in participants, 17 were stopped by PrEP. 

alt

Read more: